English
Calliditas is focused on the development and commercialization of its lead product candidate Nefecon.
A potential treatment for patients with IgA nephropathy at risk of developing ESRD.
Calliditas shortlisted in two categories at the European Lifestars Awards: Post-IPO Equity Raise of the Year and Deal of the Year (<£500m)
On November 14, 2019, Calliditas Therapeutics published its business update for the third quarter 2019.